These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 18551855

  • 21. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
    Baskaran ND, Gan GG, Adeeba K.
    Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
    [Abstract] [Full Text] [Related]

  • 22. Advances in management of low-risk febrile neutropenia.
    Teuffel O, Sung L.
    Curr Opin Pediatr; 2012 Feb; 24(1):40-5. PubMed ID: 22037219
    [Abstract] [Full Text] [Related]

  • 23. Management of febrile neutropenia in pediatric oncology patients: a Canadian survey.
    Boragina M, Patel H, Reiter S, Dougherty G.
    Pediatr Blood Cancer; 2007 May; 48(5):521-6. PubMed ID: 16724314
    [Abstract] [Full Text] [Related]

  • 24. Outpatient treatment with intravenous antimicrobial therapy and oral levofloxacin in patients with febrile neutropenia and hematological malignancies.
    Bellesso M, Costa SF, Pracchia LF, Santos Dias LC, Chamone D, Dorlhiac-Llacer PE.
    Ann Hematol; 2011 Apr; 90(4):455-62. PubMed ID: 20852999
    [Abstract] [Full Text] [Related]

  • 25. Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies.
    Feld R, Paesmans M, Freifeld AG, Klastersky J, Pizzo PA, Rolston KV, Rubenstein E, Talcott JA, Walsh TJ, Immunocompromised Host Society, Multinational Association for Supportive Care in Cancer.
    Clin Infect Dis; 2002 Dec 15; 35(12):1463-8. PubMed ID: 12471564
    [Abstract] [Full Text] [Related]

  • 26. [Prognostic risk factors for serious complications in an inpatient population with neutropenia at the onset of a febrile episode].
    Gómez Roca C, Rivero M, Hugo K, Novillo A, Marta Lapadula M, Recondo G, Milberg M.
    Medicina (B Aires); 2006 Dec 15; 66(5):385-91. PubMed ID: 17137166
    [Abstract] [Full Text] [Related]

  • 27. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study.
    Brack E, Bodmer N, Simon A, Leibundgut K, Kühne T, Niggli FK, Ammann RA.
    Pediatr Blood Cancer; 2012 Sep 15; 59(3):423-30. PubMed ID: 22271702
    [Abstract] [Full Text] [Related]

  • 28. Outpatient management of febrile neutropenia: is it safe yet?
    Johnson TN, DeJesus YA, McMahon L, Rolston KV, Row MB.
    J Support Oncol; 2008 Sep 15; 6(5):219-20. PubMed ID: 18551857
    [No Abstract] [Full Text] [Related]

  • 29. [Febrile neutropenia].
    Bally F, Marchetti O, Cometta A.
    Rev Prat; 2003 Dec 15; 53(19):2101-7. PubMed ID: 15008466
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Outpatient high-dose melphalan in multiple myeloma patients.
    Kassar M, Medoff E, Seropian S, Cooper DL.
    Transfusion; 2007 Jan 15; 47(1):115-9. PubMed ID: 17207239
    [Abstract] [Full Text] [Related]

  • 32. [Consensus: Rational approach towards the patient with cancer, fever and neutropenia].
    Santolaya ME, Rabagliati R, Bidart T, Payá E, Guzmán AM, Morales R, Braun S, Bronfman L, Ferrés M, Flores C, García P, Letelier LM, Puga B, Salgado C, Thompson L, Tordecilla J, Zubieta M, Sociedad Chilena de Infectología, Sociedad Chilena de Hematología.
    Rev Chilena Infectol; 2005 Jan 15; 22 Suppl 2():S79-113. PubMed ID: 16311689
    [Abstract] [Full Text] [Related]

  • 33. Evaluation of guideline for treatment of febrile neutropenia in pediatric cancer at Siriraj Hospital.
    Sanpakit K, Phuakpet K, Veerakul G, Narkbunnam N, Chokephaibulkit K.
    J Med Assoc Thai; 2005 Nov 15; 88 Suppl 8():S124-34. PubMed ID: 16858853
    [Abstract] [Full Text] [Related]

  • 34. Safety and costs of treating neutropenic fever in an outpatient setting.
    Del Prete SA, Ryan SP, Jacobson JS, Erichson RB, Weinstein PL, Grann VR.
    Conn Med; 1999 Dec 15; 63(12):713-7. PubMed ID: 10659471
    [Abstract] [Full Text] [Related]

  • 35. Risk assessment and treatment of low-risk patients with febrile neutropenia.
    Kern WV.
    Clin Infect Dis; 2006 Feb 15; 42(4):533-40. PubMed ID: 16421798
    [Abstract] [Full Text] [Related]

  • 36. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia.
    Donohue R.
    Oncol Nurs Forum; 2006 Nov 03; 33(2):347-52. PubMed ID: 16518450
    [Abstract] [Full Text] [Related]

  • 37. Outpatient Management of Febrile Neutropenia: Should We Change the Standard of Care?
    Talcott JA.
    Oncologist; 1997 Nov 03; 2(6):365-373. PubMed ID: 10388071
    [Abstract] [Full Text] [Related]

  • 38. [Febrile neutropenia in the child with cancer. Current concepts about risk assessment and selective management].
    Santolaya ME.
    Rev Med Chil; 2001 Dec 03; 129(12):1449-54. PubMed ID: 12080883
    [Abstract] [Full Text] [Related]

  • 39. Is it time to redefine the management of febrile neutropenia in cancer patients?
    Anaissie EJ, Vadhan-Raj S.
    Am J Med; 1995 Mar 03; 98(3):221-3. PubMed ID: 7872336
    [No Abstract] [Full Text] [Related]

  • 40. The outpatient management of febrile neutropenia in cancer patients.
    Freifeld AG, Pizzo PA.
    Oncology (Williston Park); 1996 Apr 03; 10(4):599-606, 611-2; discussion 615-6. PubMed ID: 8723296
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.